Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT for Recurrent C. Difficile in SOT Recipients
NCT03617445Phase 2Terminated
- Sponsor
- University of Wisconsin–Madison
- Start
- Aug 2022
- Primary completion
- Jun 2023
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
A Phase 2 trial of MTP-101 in Clostridioides difficile infection (CDI), sponsored by University of Wisconsin–Madison. Started Aug 2022; status: terminated.
02
Drugs
MTP-101
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT03617445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03617445.